Docoh
Loading...

UTHR United Therapeutics

Filed: 7 Jun 21, 6:01am

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  June 7, 2021

 

United Therapeutics Corporation

(Exact Name of Registrant as Specified in its Charter)

 

Delaware 000-26301 52-1984749
(State or Other (Commission (I.R.S. Employer
Jurisdiction of File Number) Identification Number)
Incorporation)    

 

1040 Spring Street  
Silver Spring, MD 20910
(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (301) 608-9292

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which
registered
Common Stock, par value $0.01 per share UTHR Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company            ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                                     ¨

 

 

 

 

 

 

Item 8.01.  Other Events.

 

On June 7, 2021, United Therapeutics Corporation issued a press release providing an update concerning its lawsuit against Liquidia Technologies, Inc. The press release is attached as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01. Exhibits

 

 

(d)  Exhibits
   
Exhibit No. Description of Exhibit
   
99.1 Press release dated June 7, 2021
104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 UNITED THERAPEUTICS CORPORATION
   
   
Dated: June 7, 2021By:/s/ Paul A. Mahon
 Name:Paul A. Mahon
 Title:General Counsel

 

3